GlobeNewswire·Nov 9, 2026, 4:04 PM ET

Oruka Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

EVERLAST-B Week 16 results for ORKA-001 showed 61% PASI 100 & 86% PASI 90 in the high-dose group, consistent with EVERLAST-A.
EVERLAST-A responses deepened to 71% PASI 100 at Week 28, six months after the final dose.
ORKA-001 Phase 3 trials in moderate-to-severe psoriasis are planned to begin in the first half of 2027 using the 600 mg dose.
52-week data from EVERLAST-A is expected in December 2026, with EVERLAST-B 52-week data expected in the second half of 2027.
ORKA-002 Phase 2 ORCA-SURGE trial enrollment is complete, with Week 16 psoriasis data expected in Q1 2027.
ORKA-002 Phase 2 ORCA-SPLASH trial for hidradenitis suppurativa is progressing with a primary endpoint of HiSCR75 at Week 16.
ORKA-004 development is on track for first-in-human initiation in Q4 2026, with Phase 2 combination studies planned for 2027.
Todd Edwards was appointed Chief Commercial Officer in August 2026, bringing over 25 years of experience.
Cash, cash equivalents, & marketable securities totaled $1.2 billion as of September 30, 2026.
Research & development expenses were $53.7 million in Q3 2026, driven by clinical trials & higher compensation.
General & administrative expenses were $8.4 million in Q3 2026, reflecting increased headcount & compensation.
Net loss for Q3 2026 was $50.0 million, compared to $30.3 million in Q3 2025.